NEW YORK (Reuters Health)—Heredity plays a substantially larger role than diet in determining serum urate levels, according to new findings in BMJ. Nearly 25% of the variation in serum urate is attributable to common genetic variants, while dietary pattern explained less than 1%, Dr. Tanya J. Major of the University of Otago in Dunedin, New…

Older Gout Patients More Likely to Develop Hearing Impairment
Previous research has established that gout and hearing loss have shared risk factors. Now, a recent study found gout itself is associated with an increased risk of hearing loss in adults 65 years and older…
Allopurinol for Gout an Unlikely Contributor to Kidney Disease
NEW YORK (Reuters Health)—Allopurinol does not appear to contribute to decline in kidney function and may actually protect renal function in patients with gout, according to a large population-based study. Gout affects around 4% of Americans and often occurs alongside chronic kidney disease (CKD), Dr. Tuhina Neogi from Boston University School of Medicine and colleagues…

Annual Meeting Preview: Rheumatology Research Foundation Activities
Another exciting ACR/ARHP Annual Meeting is planned for this October. Show your support for the Foundation’s mission and enjoy your time in vibrant Chicago at one of the Foundation’s many events. Donations made to the Foundation support the extensive awards program that funds research, training and education opportunities for current and potential rheumatologists and rheumatology…

5 Takeaways from the ACR’s Gout Clinical Quality Measures
With electronic clinical quality measures tailored for treating gout patients, physicians and their teams now have tools to measure and improve gout care performance and outcomes…

Gout Emergency Department Visits Up
In the past nine years, visits to the emergency department by gout patients have increased by almost 27%. Researchers suggest physicians may not adequately be addressing the burden of gout and the underlying accumulation of uric acid, driving the dramatic increase in emergency department visits in the U.S…

New Study Raises Cardiovascular Questions about Febuxostat for Gout
New research raises questions about the cardiovascular safety of febuxostat for gout patients compared with allopurinol. The study found that although febuxostat was noninferior to allopurinol, febuxostat-treated patients had similar overall rates of major adverse cardiovascular events as allopurinol-treated patients, but had higher rates of all-cause mortality and cardiovascular mortality…

Reduced Serum Uric Acid Levels May Protect Against Renal Function Decline
New research examined the link between a reduction in serum uric acid (SUA) levels and the reduced risk of renal function decline in patients with gout. The findings suggest that aggressive serum acid-lowering approaches may be helpful in slowing the progression of renal disease…

Pathophysiology of Gouty Tophi
In a recent study, researchers examined synovial fluid and non-inflamed tophi from the acutely inflamed joints of patients with gout, finding that monosodium urate (MSU) crystals trigger a distinct physiological NETosis pathway that coats MSU crystals in DNA that persists in tissues as gouty tophi…
Study Finds Newer Gout Drug Poses Risk to Heart Patients
(Reuters Health)—Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded. The risk of death from cardiovascular disease was 34% higher with febuxostat than with allopurinol. When researchers considered deaths from any cause, the risk was 22% higher…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 21
- Next Page »